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In the limbic brain,mineralocorticoid receptors (MRs) andglucocorticoid receptors (GRs) both function as
receptors for the naturally occurring glucocorticoids (corticosterone/cortisol) butmediate distinct effects
oncellularphysiologyvia transcriptionalmechanisms. The transcriptionalbasis for specificityof theseMR-
vs GR-mediated effects is unknown. To address this conundrum,we have identified the extent ofMR/GR
DNA-binding selectivity in the rat hippocampus using chromatin immunoprecipitation followed by
sequencing. We found 918 and 1450 nonoverlapping binding sites for MR and GR, respectively. Fur-
thermore, 475 loci were co-occupied byMR and GR. De novomotif analysis resulted in a similar binding
motif for both receptors at 100% of the target loci, which matched the known glucocorticoid response
element (GRE). In addition, the Atoh/NeuroD consensus sequence was found in co-occurrence with all
MR-specific binding sites butwas absent forGR-specific orMR-GRoverlapping sites. Basic helix-loop-helix
family members Neurod1, Neurod2, and Neurod6 showed hippocampal expression and were hy-
pothesized tobind theAtohmotif. Neurod2wasdetectedat rat hippocampalMRbinding sitesbutnot at
GR-exclusive sites. All three NeuroD transcription factors acted as DNA-binding–dependent coactivators
for bothMR and GR in reporter assays in heterologous HEK293 cells, likely via indirect interactions with
the receptors. In conclusion, aNeuroDfamilymemberbinding toanadditionalmotif near theGRE seems to
drive specificity forMRoverGRbindingathippocampalbindingsites. (Endocrinology158:1511–1522,2017)
The endogenous glucocorticoid hormone of the rat,corticosterone, has a profound action on the brain.
This action is mediated in a complementary manner by
mineralocorticoid receptors (MRs) and glucocorticoid
receptors (GRs), which are unevenly distributed over the
brain, but coexpressed in abundance in the hippocampus
(1). The high-affinity MRs are already substantially oc-
cupied with low corticosterone levels (2). In the initial
response to stress, these MRs play a crucial role in re-
trieval of stressful information and the selection of an
appropriate coping response (3–5). In contrast, the lower-
affinity GRs become activated only at higher cortico-
sterone levels, around the peak of the circadian rhythm
and during a stress response. GR activation promotes
memory storage of the stressful experience (6, 7) and
behavioral adaptation and recovery (1, 8).
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Much progress has been made in understanding the
cellular mechanism of these coordinatedMR–GR–mediated
actions of corticosterone (9). Many of the effects depend on
the transcriptional activity of the receptors. MR-mediated
actions generally raise excitability in the hippocampus. In the
most ventral part of the hippocampus, corticosterone pro-
longs excitability via GR, providing an extended period for
encoding of new information. In the dorsal pyramidal cells,
GR-mediated actions oppose those mediated by MR (10).
That these MR- and GR-mediated effects of corticosterone
are sometimes overlapping and, in other processes, are dis-
tinct is remarkable, given the large structural similarity be-
tween the two receptor types.
MR and GR are members of the nuclear receptor family,
with a modular structure of an N-terminal domain, a DNA-
binding domain (DBD) and C-terminal ligand-binding do-
main (LBD).Upon ligandbinding, the receptors can dimerize
and translocate to the nucleus, where they alter the tran-
scription of their target genes. MR and GR can affect gene
expression via tethering to other proteins such as AP-1 and
NFkB (11), but in the hippocampus, at least under basal
conditions, the mainmechanism seems to be via direct DNA
binding to the glucocorticoid response element (GRE), pal-
indromic sequences that are variations of AGAACANN-
NTGTTCT (12).Homodimers aswell as heterodimers of the
receptors may occur (13, 14). The intrinsically unstructured
N-terminal domain contains an Activator Function (AF)-1,
and the LBD contains a ligand-dependent AF-2. Through
these AF domains, the receptors can interact with cor-
egulators, which can modulate the transcriptional effects by
histone-modifying activity and recruitment/stabilization of
the transcription factor complex (15). The fact that the two
receptors are 94% identical in their DBD (16) suggests that
other mechanisms must exist that confer transcriptional
specificity underlying the differential effects of MR/GR.
It has remained elusive to what extent genomic targets of
MR and GR overlap and what determines the specificity of
MRandGRDNAbinding.We previously identified genomic
loci forGR,usingchromatin immunoprecipitation-sequencing
(ChIP-seq) after a single injection of corticosterone (12). In this
study, we aimed to characterize mechanisms that confer MR/
GR specificity by directly comparing their genomic binding
sites in the same tissue. Our findings suggest that interactions
betweenMR/GRandDNA-binding transcription factors from
theNeuroD family are responsible forMR-selective signaling
in the limbic brain and that NeuroD factors are able to po-
tentiate transcriptional activity of both receptor types in vitro.
Material and Methods
In vivo experiment
For the ChIP-seq experiment, adult male Sprague-Dawley
rats (Harlan, The Netherlands) were housed on a 12-hour
light/12-hour dark cycle (lights on at 7:30 AM) with food and
water ad libitum. ChIP-seq with MR, GR, or control immu-
noglobulin G (IgG) antibody was performed on hippocampal
tissue of three-day adrenalectomized animals 60 minutes after a
single intraperitoneal injection of 300 or 3000 mg/kg cortico-
sterone as a 2-hydroxypropyl-b-cyclodextrin complex, as de-
scribed (12). ChIP-seq was done on pooled tissue from six
animals per treatment, which was redivided, leading to four
technical ChIP replicates for both MR and GR. All experiments
were performed according to the European Commission
Council Directive 2010/63/EU and the Dutch law on animal
experiments and approved by the animal ethical committee
from Leiden University.
ChIP-seq analysis and motif search
The MR binding data were generated and analyzed in
parallel with the previously published data for GR (12). Illu-
mina Genome Analyzer 35-bp single-end reads were uniquely
mapped to the rattus norvegicus genome version 4. Peaks were
called using model-based analysis of ChIP-Seq (MACS) (17)
with the IgG antibody binding dataset as the background.
Binding sites were considered overlapping if more than 4 bp
were shared. Data were visualized by uploading wiggle files to
the Integrative Genomics Viewer (18). Using the annotate peak
function of HOMER, binding sites were associated to their
nearest gene (19). The Database for Annotation, Visualization,
and Integrated Discovery was used for gene ontology analysis
(20). Binding sequences were analyzed for the presence of de
novo motifs using multiple expectation maximization for motif
elicitation (21). The motif size was set from 6 bp minimum to
20 bp maximum, searching also the reverse complement, with a
maximum of 10 output motifs, using random, shuffled input se-
quences as the backgroundmodel. Enrichedmotifswere compared
against the JASPARvertebrate database of knownmotifs using the
TOMTOMmotif comparison tool. Analysis ofMotif Enrichment
(AME) was used for enrichment analysis of knownmotifs inMR-
exclusive relative to GR-exclusive binding sequences, and Motif
Alignment and Search Tool (MAST) was used for directed search
of motifs of interest, under default settings (21).
ChIP-qPCR validation
For binding site validation, we performed ChIP-quantitative
polymerase chain reaction (qPCR) on hippocampal tissue of
intact rats killed at the time of their endogenous corticosterone
peak. Antibodies used are listed in Supplemental Table 1.
Protease inhibitors (Roche) were added to all buffers during
tissue processing and the ChIP procedure. Hippocampal
hemispheres were fixated with 1% formaldehyde for 12 to 14
minutes and were homogenized in Jiang buffer [0.32M sucrose,
5 mM CaCl2, 3 mM Mg(Ac)2, 0.1 mM EDTA, 10 mM tris
(hydroxymethyl)aminomethane-HCl, pH 8.0, 0.1% Nonidet P
(NP)-40] using a glass douncer (Kimble-Chase). The following
steps were performed in NP buffer [150 mMNaCl, 50 mM tris
(hydroxymethyl)aminomethane-HCl, pH 7.5, 5 mM EDTA,
0.5%NP-40, 1%TritonX-100]. Chromatinwas fragmented by
sonication for 32 minutes with 30-second ON/30-second OFF
cycles, using a Bioruptor Pico (Diagenode). Three processed
hippocampal hemispheres were pooled and redivided to
perform a ChIP for both MR and Neurod2. From each chro-
matin sample, an aliquot was taken as input material to be able
to calculate the percentage of immunoprecipitated DNA.
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Chromatin (500 mL) was incubated overnight with 6 mg anti-
body, after which 20 mL protein A Sepharose beads (GE
Healthcare) was added for 2.5 hours. After several washing
steps (Supplemental Methods), antibody-bound DNA was
eluted from the beads using 10%Chelex 100 (Bio-Rad), further
purified by phenolization and dissolved in 50 mL H2O. qPCR
was performed on 4x diluted ChIP samples according to the
protocol described below. Primers were designed to span the
GRE of the discovered binding sites and are listed in Supple-
mental Table 2.
Reporter assays
For mechanistic insights into the effect of NeuroD factors
on MR/GR promoter activity, we performed luciferase re-
porter assays. HEK293 cells (human embryonic kidney, fe-
male) were cultured in Dulbecco’s Modified Eagle Medium
with GlutaMax (Gibco) containing 100 U/mL penicillin, 100
mg/mL streptomycin (Gibco) and 10% fetal bovine serum
(PAN-Biotech) at 37°C under 5% CO2. For the reporter
assays, cells were seeded in a 24-well plate at a density of
80,000 cells/well and grown in medium supplemented with
charcoal-stripped fetal bovine serum (Sigma) to exclude
cortisol action from the serum. Cells were transfected on
day 2 with luciferase construct (TAT1-Luc or TAT3-Luc:
25 ng/well; GRE-At, MRE-At, or GRE-MutAt: 30 ng/well),
expression vector for one of the receptors (MMM, DMM,
MMD, GGG, DGG, GGD: 10 ng/well), and pCMV-Myc-
Neurod1/2/6 (0-1-3-10-50-100 ng/well) and completed
with pcDNA3.1 to a total of 300 ng/well and 1.25 mL/well
FuGENE (Promega) in unsupplemented Dulbecco’s Modified
Eagle Medium. Renilla luciferase was used to correct for
transfection efficiency (1 ng/well, pRL-CMV; Promega). On
day 3, cells were stimulated with corticosterone (10–7 M or at
indicated concentrations; Sigma) dissolved in ethanol, and
diluted in medium with a final concentration of 0.1% eth-
anol. After 24 hours, the cells were washed with phosphate-
buffered saline, and reporter protein was measured using the
Dual-Luciferase Reporter Assay System according to the
manufacturer’s instruction (Promega). Briefly, 100 mL lysis
buffer was added, and after 10 minutes, 10 mL lysate was
transferred into a half-area 96-well plate. Luciferase levels
were quantified with 25 mL luciferase assay substrate at
570 nm; subsequently, Renilla signal wasmeasured at 470 nm
after the addition of 25 mL Stop and Glo at a SpectraMax L
microplate reader (Molecular Devices). All data are presented
as mean 6 standard error of the mean. Reporter assays were
done in triplicates and repeated at least once.
Plasmids
The GRE-At and GRE-MutAt luciferase constructs were
created by inserting a 36-bp fragment containing a perfect palin-
dromic GRE plus the Atoh1 motif or the GRE with a scrambled
motif in the XhoI site of a pGL4.10[luc2] vector (Promega). Inserts
were GRE-At: ctcgagGATGGCAGATGGAGCTAAGAACA-
GAATGTTCTATAActcgag and GRE-MutAt: ctcgagGATG-
GAGCGGATAGCTAAGAACAGAATGTTCTATAActcgag.
The MRE-At luciferase construct was created by inserting a 35-bp
endogenously found MR binding site containing a more degen-
erate GRE plus the Atoh1 motif in the NheI/BglII site of
the same pGL4 vector. MRE-At insert was: gctagcGCACA-
CAGATGAGTGGGGATCTGAATGTACTGTGGagatct. The
pCMV-Myc-Neurod6 expression vector was kindly provided by
Dr. Mitsuhiko Yamada (22). Neurod1 and Neurod2 were
amplified from Sprague-Dawley rat hippocampal complemen-





respectively, and cloned in frame into the SalI/XhoI site of the
same pCMV-Myc vector to gain pCMV-Myc-Neurod1 and
pCMV-Myc-Neurod2. Expression vectors for rat receptors
6RMR (MMM), 6RGR (GGG), and their corresponding truncated
receptors 6RMR/596C (DMM), 6RMR/N689 (MMD), 6RGR/
407C (DGG), 6RGR/N525 (GGD), and TAT1/3-Luc reporters
were kindly provided by Dr. David Pearce (23).
Real-time qPCR
To validate the NeuroD factor expression in the rat brain,
we performed reverse transcription (RT)-qPCR measure-
ments on Sprague Dawley tissue. Hippocampal hemispheres
were homogenized in TriPure (Roche) by shaking the tissue
with 1.0-mm-diameter glass beads for 20 seconds at 6.5 m/s
in a FastPrep-24 5G instrument (MP Biomedicals). Total
RNA was isolated with chloroform, precipitated with iso-
propanol, washed with 75% ethanol, and resuspended in
nuclease-free H2O. The purity and concentration of the
RNA samples were measured on a NanoDrop 1000 spec-
trophotometer (Thermo Scientific). cDNA was reverse
transcribed from 1 mg RNA using random hexamers and
M-MLV reverse transcription (Promega) and incubated for
10 minutes at 25°C, 50 minutes at 45°C, and 10 minutes at
70°C. RT-qPCR was performed in duplo on 103 diluted
cDNA (5 ng/mL) with final primer concentrations of 0.5 mM
using GoTaq qPCR master mix (Promega) in a CFX96 real-
time PCR machine (Bio-Rad). The program consisted of 40
cycles of 10 seconds at 95°C and 30 seconds at 60°C, fol-
lowed by a melting curve generation from 65°C to 95°C in
steps of 0.5°C. Primer sequences are listed in Supplemental
Table 2.
Allen Brain Atlas correlations
Lists of MR-exclusive, MR-GR overlapping, and GR-
exclusive genes corresponding to the intragenic and distal
promoter (up to –5000 bp) ChIP-seq binding sites were
evaluated for their coexpression with each studied NeuroD
factor, using the mouse brain gene expression data from the
Allen Brain Atlas (24). Pearson’s correlation coefficient was
used as a measure of similarity between the expression
profile of the seed genes (Neurod1, Neurod2, and Neurod6)
and every gene in the three aforementioned lists within an
anatomical region of interest (25). Correlations were cal-
culated in the hippocampus and its subregions cornu
ammonis (CA)1 to CA3 and the dentate gyrus (DG) as well
as the striatum. To assess the strength of the association
between each gene list and a seed gene, we used a one-sided
Wilcoxon rank-sum test.
Data deposition
ChIP-seq data have been submitted to the European Nu-
cleotide Archive and will be available under accession number
PRJEB18916.
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Results
MR-GR binding site overlap
ChIP-seq on hippocampus chromatin with MR and
GR antibodies resulted in the generation of 1.3 to 1.9 3
107 reads per sample. After uniquely mapping 66.6% to
83.5% of these reads to the rat genome (rattus norvegicus
genome version 4), MACS peak calling with a false
discovery rate cutoff at 13.5% [conform (12); Supple-
mental Fig. 1(a)] resulted in 768 MR sites in the animals
injectedwith 300mg/kg (MR300) and 1465MR sites and
2460 GR sites in the animals injected with 3000 mg/kg
(MR3000 and GR3000).
We computed the overlap in binding-site genomic
coordinates for MR and GR [Fig. 1(a)]. Additional fil-
tering of MR- and GR-exclusive sites demanded total
absence of any peak (the MACS lists including those
peaks with a false discovery rate above 13.5%) at the
same locus in the GR and MR data, respectively. This
resulted in 918 MR-exclusive sites (combined from the
MR300 andMR3000 dataset), 475MR-GR overlapping
sites, and 1450 GR-exclusive sites (Supplemental Ta-
ble 3). These correspond to 45.9% of the total MR sites
and 58.9% of the total GR sites being nonoverlapping.
ChIP-seq traces of anMR-exclusive,MR-GR overlapping,
and GR-exclusive peak are shown in Supplemental Fig-
ure 2. The distribution of sites relative to nearest genes is
similar for these subsets, with approximately 40% to 45%
of the binding sites located within promoters and genes,
mainly in introns [Supplemental Fig. 1(b)]. Limited overlap
was found between the MR binding sites for the two
different dosages, as only 30.6% of the MR300 sites were
also found in the MR3000 dataset.
Validation of MR binding sites
TheGRbinding siteswere thoroughly validated before
(12). We performed ChIP-qPCR measurements for MR
in the hippocampus of intact animals killed at the time
of their endogenous corticosterone peak. MR binding
was detected at all tested MR-exclusive sites, whereas no
MR signal was found at any of the GR-exclusive sites
[Fig. 2(a)]. This demonstrates that the selectivity found in
the pharmacological ChIP-seq experiment also occurs
in a physiological context.
Processes associated with MR and GR target genes
The biological relevance of the hippocampal binding
sites was examined by gene ontology enrichment analysis
of target genes, under the assumption that expression of
MR/GR bound genes will be regulated by the receptor.
Intragenic and upstream (up to –5 kb) binding sites were
annotated to generate lists ofMR-exclusive, overlapping,
and GR-exclusive target genes (Supplemental Table 4).
Functional annotation clustering using the Database for
Annotation, Visualization, and Integrated Discovery
showed enrichment of brain-related terms, such as
“Regulation of cell projection assembly” (MR), “Syn-
apse, Regulation of synaptic plasticity” (overlapping),
and “Cell/neuron projection, Synaptic vesicle” (GR)
(Supplemental Table 5). Interestingly, for those genes
linked to specific MR binding, there was enrichment for
“Sodium channel activity,” “Calcium ion transport,”
and “Ion transport, voltage-gated channel activity.”
Another term specific for MR-exclusive target genes was
“Cell adhesion.”Furthermore, the annotatedGR-exclusive
target genes were associated with “Apoptosis and Re-
sponse to oxidative stress.”
An additional motif was found near
MR-exclusive sites
To explore the biological mechanism underlying MR/
GR-selective binding, we performed de novo motif
analysis on the binding site sequences. For theMR as well
as the overlapping and GR datasets, all sites contained a
GRE [Fig. 1(b)]. This is in contrast to the aldosterone-
inducedMR cistrome in a human renal cell line, where the
majority of binding sites lack a GRE (26). The MR-
exclusive sites had a more degenerate GRE (lower
probability of bases) than the GR-exclusive sites. All
subsets also contained a motif that matched the ZNF263
binding site, which was present in 18% to 67% of the
sequences. The MR-GR overlapping sites all contained a
motif that resembles a GRE half site, suggestive of con-
comitant dimeric andmonomeric (or multimeric) binding
of the receptors.
Interestingly, we found a distinct motif near the MR-
exclusive sites that was not enriched near the GR-
exclusive or overlapping sites. This additional motif
was present in 100% of the MR sites and matched to the
Atoh1 binding sequence in the motif database. In a di-
rected search, the Atoh1 motif was also enriched in MR
over GR binding (AME; P = 1.11 3 10–24), although in
individual cases, we observed this site near GR-bound
GREs (MAST; 1% of the GR-exclusive sites). The dis-
tance between the GRE and Atoh motif was normally
distributed [Fig. 1(c)] and independent of their respective
orientation/strand (in or out of phase) or the binding site
relative to genes (intergenic vs intragenic) [Supplemental
Fig. 1(c)]. We supposed that another protein binding to
this Atoh site can drive MR-specific binding.
NeuroD family members as candidate binders
According to the Allen Brain Atlas (24), Atoh1 is not
expressed in themouse hippocampus (Fig. 3; Table 1) and
is therefore not considered a candidate to bind the MR-
specific motif found in the hippocampal ChIP-seq dataset.
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Figure 1. ChIP-seq binding site analysis. (a) Overlap of MR and GR binding sites in the rat hippocampus, from animals injected with 300 mg/kg
(MR300) or 3000 mg/kg (MR3000 and GR3000) corticosterone. Dashed lines represent the additional filtering of nonoverlapping sites demanding
total absence of any peaks in the other receptor dataset, leading to 918 MR-exclusive (combined from MR300 and MR3000), 475 overlapping,
and 1450 GR-exclusive sites. (b) De novo motif analysis of MR-exclusive, overlapping, and GR-exclusive binding sites. Discovered motifs are
depicted with their E-value (multiple expectation maximization for motif elicitation) and the highest-ranked matching transcription factor (TF).
Listed transcription factors are followed by the E-value (TOMTOM) for the motif comparison. (c) Distribution of distance between GRE and Atoh
motifs over 25-bp bins, including a normal curve. Depletion of the histogram bin around zero is due to the minimum distance of 8 bp as
calculated from the center of the GRE to the center of the Atoh motif.
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Atoh1 belongs to the basic helix-loop-helix (bHLH)
family of transcription factors (27). Brain-specific family
members Neurod1, Neurod2, and Neurod6 do show
evident hippocampal expression (Fig. 3) and have been
shown to bind the identified CAGATGGmotif (28–30).
We validated the very low expression levels (or ab-
sence) of Atoh1 and expression of the three NeuroD
genes in the rat hippocampus by RT-qPCR (Table 1)
and hypothesized (one of) these corresponding proteins
could be responsible for the binding site selectivity
for MR.
By ChIP-qPCR, we demonstrated Neurod2 binding at
the same sites at whichwe validatedMRbinding [Fig. 2(b)].
It was however absent from GR-exclusive loci. This gives a
proof of concept thatNeurod2might be binding to theAtoh
site in vivo. Although Neurod2 was selected based on
the availability of chromatin immunoprecipitation–grade
antibodies, this result does not exclude involvement of
Neurod1 or Neurod6 in MR-selective signaling.




To get an indication if the
other two NeuroD factors
could be (co)responsible for
the MR-selective binding in
vivo, we examined to what
extent they are coexpressed
with putative MR/GR target
genes (as defined by intragenic
or up to –5-kb binding of MR
or GR). We assessed the spa-
tial coexpression of the MR,
overlapping, and GR target
gene lists with each of the
NeuroD family members based
on their expression patterns
across the brain using data
from the Allen Brain Atlas
(24). The MR targets had
a stronger coexpression with
Neurod6 than the overlapping
or GR targets, while for
Neurod2, there was no dif-
ference between the three lists,
and the Neurod1 spatial cor-
relation was highest for the
GR targets (Supplemental
Fig. 3). This could argue for
Neurod6 as an in vivo deter-
minant of MR-selective signal-
ing. Nevertheless, all three
NeuroD factors correlated strongly with the expression
of MR-exclusive targets and were subsequently studied
in vitro.
NeuroD family members potentiate MR/GR
transactivation
The putative role of Neurod1, Neurod2, and Neurod6
in MR-specific signaling was further studied in reporter
assays in HEK293 cells. All three proteins potentiated
MR but unexpectedly also GR transactivation upon
corticosterone treatment on a luciferase construct
containing a GRE plus the additional Atoh motif in its
promoter (GRE-At) by approximately fourfold and
sevenfold to ninefold, respectively (Fig. 4). This effect was
not observed at a control construct lacking the Atoh
binding site (GRE-MutAt), and the NeuroDs could not
enhance reporter expression without hormone stimula-
tion. The NeuroD factors thus acted as MR/GR tran-
scriptional coactivators via the identified Atoh motif. For
Figure 2. ChIP-qPCR validation of (a) MR (n = 5) and (b) Neurod2 (n = 6) binding to a subset of MR-
exclusive and GR-exclusive binding sites. Numbers indicate the fold induction over IgG background.
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Neurod6, a clear dose- response curve was observed for
transfection with increasing doses of expression vector
[Supplemental Fig. 4(a)]. We further tested a reporter
driven by a more degenerate GRE, as found for the MR-
exclusive sites [Fig. 1(b)], combined with the additional
Atoh site (MRE-At). The receptors were less efficient in
stimulating this luciferase promoter, and the NeuroD
effect also did not differ for MR and GR on this reporter
[Supplemental Fig. 4(b)].
NeuroD family members increase mainly the
maximum transcriptional effect
As the mechanism of action of a receptor modulator
can be deduced from both the change in maximum effect
as well as the ligand concentration needed for 50% of
this effect (EC50) (31), we generated corticosterone
dose-response curves with and without cotransfecting
Neurod6. The maximumMR/GR effect was increased by
Neurod6 presence over the whole concentration range
that activates the receptor (data not shown), as was seen
before by increased luciferase expression at saturating
corticosterone concentrations of 10–7M
(Fig. 4). Besides, the EC50 was not
changed forMR (2.2460.06310–10M
vs 1.89 6 0.05 3 10–10 M), while the
GR showed a slightly decreased EC50
uponNeurod6 addition (1.036 0.053
10–8 M vs 5.29 6 0.02 3 10–9 M)
[Fig. 5(a)].
NeuroD family members interact
with both N- and C-terminal
domain–lacking receptors
To further investigate the mecha-
nism of interaction between the MR/
GR and NeuroD factors, reporter as-
says were performed using truncated
receptors [Fig. 5(b)]. The trans-
activation by receptors lacking the
LBD (MMD and GGD) could be po-
tentiated by the different NeuroDs,
although to a lesser extent than for
the full-length receptors (MMM and
GGG). The potentiation by NeuroDs
was also seen without hormone treat-
ment of these constitutively active re-
ceptors lacking the LBD. Besides, the
NeuroDs could also increase tran-
scriptional activity of the receptors
that did not have an N-terminal do-
main (DMM and DGG). For MR,
the NeuroD potentiation of the trun-
cate was comparable to that for the
full-length receptor, but for GR, the enhancement relative
to nonstimulated cells was less than one-half that of the
full-length receptor. Unexpectedly, the DMM and DGG
were unresponsive to corticosterone treatment at this
reporter, but we did confirm proper transactivation at
TAT1-Luc and TAT3-Luc reporters (data not shown).
This potentiation of both N- and C-terminal receptor
truncations suggests that NeuroD factors have an indirect
interaction with MR/GR.
Discussion
This study examined the overlap and specificity ofMR vs
GR regarding whole-genome hippocampal binding sites.
We found both MR-specific, GR-specific, and joint sites,
which all contained aGRE. Virtually allMR-specific sites
had an Atoh consensus sequence within 400 bp of the
GRE, whereas de novo motif analysis did not find this
sequence near sites that showedGRoccupancy (including
overlapping sites). Neurod1, Neurod2, and Neurod6
are coexpressed with MR and/or GR in the principal
Figure 3. Expression of MR, GR, Atoh1, and NeuroD family members in the adult mouse
hippocampus, with the corresponding reference atlas. Visualizations of the sagittal in situ
hybridization (ISH) experiments and corresponding background-subtracted signals (Expression)
from the Allen Brain Atlas (24). Experiment_position numbers of depicted images are listed in
Supplemental Methods.
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hippocampal cell layers, and all could act as coactivators
of both MR and GR in reporter assays.
The limited overlap found inMR andGR binding sites
is in accordance with the distinct roles of the two re-
ceptors in the hippocampus (6, 10, 32). It should be noted
however that the lower sequencing depth of our analysis
might have precluded the detection of weaker binding
sites. In addition, as we performed ChIP-seq on whole
hippocampi, the small proportion of shared targets could
also be a result of cell type–specific MR/GR loci as a
consequence of the differential MR and GR expression
patterns throughout the hippocampal area. Coexpression
of MR and GR is observed in the majority of CA py-
ramidal and DG granular neurons, with the exception of
CA3 pyramidal cells that have highMRbut lowGR levels
(33). Besides, GR is also expressed in glial cells (34, 35).
Limited overlap in the MR binding sites for the two
different corticosterone doses (MR300 vs MR3000)
could be explained partly by an insufficient depth of
sequencing (limit of detection). In addition, it might re-
flect different concentrations of activated MR in the
nucleus, in combination with differential affinity of
binding sequences for the receptor, even if the majority of
MR likely was occupied by the lower dose. A recent study
suggests that high receptor occupancy does not neces-
sarily translate into high DNA binding, and MR can
show circadian variation in target site occupancy (36).
Differences in sensitivity between MR-expressing cell
types might also be of relevance. A last possibility may be
opening up of chromatin domains via GR, making GREs
available for MR binding. In the same line, hetero-
dimerization of MR and GR could play a role (36).
The additional MR-selective motif could be bound by
Neurod1, Neurod2, and Neurod6, as evidenced by re-
sponse element–dependent transcriptional modulation.
NeuroD proteins are members of the bHLH protein
family and are known for their function in neuronal
differentiation (28, 37). Neurod1 knockout mice lack
a dentate granule cell layer (38), and heterozygous
Neurod2-deficient mice show impaired contextual and
cued freezing in a fear-conditioning task (29). Our
binding sites were detected in adult rat hippocampal
tissue, suggesting that the NeuroD factors not only
regulate neuronal differentiation during development,
but also can be crucial in later processes such as
cell survival or retaining differentiation status. As the
hippocampal DG is the main site of adult neurogenesis
(39), this might also provide a role for NeuroD factors
in adulthood, although their expression is much wider
than neurogenic zones. Furthermore, overexpression of
Neurod2 in the ventral hippocampus has recently been
shown to increase stress susceptibility in a chronic social
defeat paradigm (40), posing a role for Neurod2 in
depression.
Based on mouse brain expression data from the Allen
Brain Atlas, we observed that Neurod6 expression is
restricted to the CA subregions of the hippocampus,
while the lower Neurod1 signal seems to be more pro-
nounced in the DG (Fig. 3). Furthermore, Neurod2 ex-
pression is observed throughout the whole hippocampus
Table 1. Overview of Atoh1 and NeuroD Family Members and Validation of mRNA Expression Levels in
Rat Hippocampus
Protein Synonyms Expression Peak
Adult Hippocampal Expression
Subregion ABA (Mouse) Ct (Rat)
Atoh1 Hath1, Math1, bHLHa14 Early embryonic — 0.24 .33.0
Neurod1 BETA2, BHF-1, Neurod,
bHLHa3
E16-P0a Both CA and DG
(higher in DG)
1.41 23.2
Neurod2 Ndrf, bHLHa1 Stable throughout
developmenta
Both CA and DG 10.41 22.0
Neurod3 Neurog1, AKA, Math4C,
bHLHa6, Ngn1
Early embryonic — 0.29 —
Neurod4 AI846749, ATH-3, Atoh3,
Math3, bHLHa4
Early embryonic — 0.12 —
Neurod5 Atoh6 — — — —
Neurod6 Atoh2, Math2, Nex,
Nex1m, bHLHa2
P5a CA1–CA3 11.73 21.0
The effect of Neurod1, Neurod2, and Neurod6 on glucocorticoid signaling was studied in vitro. Raw expression value in adult mouse hippocampal
formation, b-actin = 21.17; as a reference, MR = 0.68, GR = 2.18. The threshold cycle (Ct) values represent RT-qPCR measurements on 5 ng/mL cDNA,
Sprague-Dawley rat whole hippocampus, b-actin = 17.8.
Abbreviations: ABA, Allen Brain Atlas.
aFrom ref. 50.
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and seems to be at levels similar to Neurod6, as we
validated by RT-qPCR on rat hippocampal tissue. The
three NeuroD proteins have a highly similar bHLH re-
gion (37), which makes it not surprising that all members
can bind the additional Atoh motif derived from our
ChIP-seq analysis and potentiateMR/GR transactivation
in reporter assays. Based on our data, we cannot pinpoint
which of the family members is/are responsible for the
MR-specific binding, although Neurod2 was detected at
rat hippocampalMR-exclusive sites [Fig. 2(b)] and target
gene correlations suggest that Neurod6 is also a likely
candidate (Supplemental Fig. 3). We cannot exclude the
possibility that another bHLH-containing protein binds
to the Atoh motif and drives the exclusive MR action.
Neurod1- or Neurod2-deficient mice that also lack
Neurod6 have more severe brain abnormalities than the
single mutants, indicating cooperation and/or partial
redundancy (41, 42). A model in which Neurod1,
Neurod2, and Neurod6 are each involved inMR-specific
signaling within a certain subregion of the hippocampus
might be considered.
The in vivo-found, MR-exclusive motif does not dis-
criminate in vitro in reporter assays. This discrepancy
could be explained by the possibility that, in the luciferase
assay, the receptors use different intermediate tran-
scriptional proteins than in the hippocampus. The ob-
served coactivation of both N- and C-terminally
truncated receptors implies that NeuroD family members
Figure 4. Potentiation of MR and GR transactivation by NeuroD family members on a luciferase construct containing a perfect GRE plus the
additional MR-exclusive motif. HEK293 cells were transfected with MR or GR, the GRE-At or GRE-MutAt luciferase constructs, and Neurod1,
Neurod2, or Neurod6 (10 ng/well) and stimulated with corticosterone (10–7 M). Nonstimulated cells were normalized to 1. a.u., arbitrary unit.
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interact via the transcriptional complex ofMR/GR rather
than directly with the receptors. A side note is that we
cannot rule out interactions via the DBD or hinge region
of the receptors. Nevertheless, the suggested indirect
interaction is also supported by the fact that the Atoh
motif was found at a variable distance up to 400 bp from
the GRE. It is likely that the HEK293 cells lack or do
contain other variants of the proteins that are crucial to
mediate the NeuroD effect on selective MR transcrip-
tional activity. For example, the pool of coregulators
present in a cell is highly tissue specific and can result in
opposite effects on gene transcription (43). Also, bHLH
protein heterodimerization partners might be responsible
for an MR-specific effect (27). Besides, as the chromatin
landscape is a crucial determinant of a transcription
factor cistrome (44), the lack of chromatin context in the
luciferase assay might make it difficult to mimic the exact
conditions of in vivo binding and transcription. In-
terestingly, Neurod1 itself can also induce chromatin
remodeling and increase neuronal gene accessibility (45).
In lung fibroblasts, the Atoh1 motif was detected,
although nonsignificantly, near GR-bound sequences
(46). Directed motif search by MAST showed the pres-
ence of aNeurod2 binding site in 1%of ourGR-exclusive
sites, but the Atoh motif was clearly enriched in MR-
exclusive over GR-exclusive sites using AME. It might
be that a NeuroD factor through binding to the Atoh
motif only excludes GR binding and subsequent trans-
activation when MR is present, which can be another
reason that we do not find a difference in MR/GR
Figure 5. NeuroD increases the maximum MR/GR effect via an indirect mechanism of action. (a) Dose-response curves for corticosterone
stimulation of MR and GR in absence and presence of Neurod6 to determine the effect on EC50. The luciferase activity is presented as
percentage of the maximum effect. Sigmoidal curves were fit by nonlinear regression using a variable slope model. (b) Effect of NeuroD factors
on truncated receptors. HEK293 cells were transfected with full MR or GR (MMM, GGG) or variants lacking the N terminus (DMM, DGG) or C
terminus (MMD, GGD), the GRE-At construct, and Neurod1, Neurod2, or Neurod6 (10 ng/well) and stimulated with corticosterone (10–7 M). All
nonstimulated cells were normalized to 1; for the constitutively active MMD and GGD, luciferase levels were normalized to nonstimulated control
cells. a.u., arbitrary unit.
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potentiation in vitro when studying the receptors in
isolation. In cotransfections of MR and GR combined
with selective pharmacological activation, both receptors
were also potentiated by Neurod6 (data not shown).
Furthermore, the highly dynamic DNA-binding kinetics
of nuclear receptors are not supportive of a competition-
based mechanism (47, 48). A recent study also found
motifs that were associated with absence of GR binding,
and proteins recognizing these sequences could indeed
decrease GR occupancy and transactivation (49).
In conclusion, we identified a motif that is associated
with MR-selective signaling in the rat hippocampus.
NeuroD factors could bind this motif and, via indirect
interactions, were found to potentiate the MR/GR
transcriptional activity in HEK293 cells. The data
support a model in which NeuroD factors stabilize MR
binding in vivo by interacting with cell-specific compo-
nents of the MR-associated transcriptional complex.
Further elucidation of distinct MR/GR downstream
pathwayswill enable us tomore specifically target aspects
of glucocorticoid signaling for treatment of stress-related
disorders.
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